[[{“value”:”
Roche reported its oral GLP-1 agonist led to an average 6.1% weight loss at four weeks, according to preliminary results from part of a Phase 1 study. The small molecule comes from Roche’s $2.7 billion acquisition of Carmot Therapeutics last year.
The post Roche Weighs In With Encouraging Early Clinical Data for Oral GLP-1 Drug appeared first on MedCity News.
“}]]
